Patents by Inventor Richard A. Banas
Richard A. Banas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220030851Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: October 5, 2021Publication date: February 3, 2022Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20200261512Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: March 30, 2019Publication date: August 20, 2020Applicant: Noveome Biotherapeutics, Inc.Inventors: Larry R. Brown, Richard A. Banas, Howard C. Wessel, Elise M. Gill
-
Publication number: 20180288998Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: May 26, 2018Publication date: October 11, 2018Applicant: Noveome Biotherapeutics, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20180271916Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: May 28, 2018Publication date: September 27, 2018Applicant: Noveome Biotherapeutics, Inc.Inventors: Larry R. Brown, Richard A. Banas, Howard C. Wessel, Elise M. Gill
-
Patent number: 9980987Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: GrantFiled: April 20, 2017Date of Patent: May 29, 2018Assignee: Noveome Biotherapeutics, Inc.Inventors: Larry R Brown, Richard A Banas, Howard C Wessel, Elise M Gill
-
Publication number: 20170216367Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: April 20, 2017Publication date: August 3, 2017Applicant: Noveome Biotherapeutics, Inc.Inventors: Larry R. Brown, Richard A. Banas, Howard C. Wessel, Elise M. Gill
-
Patent number: 9574177Abstract: The invention is directed to methods for reducing the number of apoptotic cell deaths in a population of cells undergoing excessive cellular apoptosis. The invention is also directed to methods for preventing apoptotic cell death in a population of cells at risk for developing excessive cellular apoptosis. In particular, the invention is directed to methods for reducing or preventing excessive cellular apoptosis comprising exposing cells exhibiting or at risk for developing excessive cellular apoptosis to a cellular factor-containing composition called Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS), which is obtained from the culturing of Amnion-derived Multipotent Progenitor (AMP) cells, or AMP cells.Type: GrantFiled: February 11, 2015Date of Patent: February 21, 2017Assignee: STEMNION, INC.Inventors: Howard C Wessel, Richard A Banas
-
Publication number: 20160367603Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: September 1, 2016Publication date: December 22, 2016Applicant: Noveome Biotherapeutics, Inc.Inventors: Richard A Banas, Catherine J Trumpower
-
Publication number: 20160081329Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: December 2, 2015Publication date: March 24, 2016Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20160015785Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: September 16, 2015Publication date: January 21, 2016Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20160000874Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: September 16, 2015Publication date: January 7, 2016Applicant: STEMNION, INC.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Publication number: 20150335712Abstract: The invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability. The invention is also directed to methods for returning vascular permeability that is a symptom of a disease or condition to a homeostatic state. Specifically, the invention is directed to methods for the treatment of diseases and conditions caused by increased vascular permeability or returning vascular permeability that is a symptom of a disease or condition to a homeostatic state by administering to a subject suffering from such diseases and conditions and symptoms novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: May 20, 2015Publication date: November 26, 2015Applicant: STEMNION, INC.Inventors: Larry R. Brown, Richard A. Banas, Howard C. Wessel, Elise M. Gill
-
Patent number: 9173908Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: February 5, 2015Date of Patent: November 3, 2015Assignee: STEMNION, INC.Inventors: Richard A. Banas, Catherine J. Trumpower, Vivienne S. Marshall
-
Publication number: 20150306149Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: July 1, 2015Publication date: October 29, 2015Applicant: STEMNION, INC.Inventors: Richard A. Banas, Catherine J. Trumpower
-
Patent number: 9138443Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: July 16, 2013Date of Patent: September 22, 2015Assignee: STEMNION, INC.Inventors: Richard A Banas, Vivienne S Marshall, Catherine J Trumpower
-
Publication number: 20150152383Abstract: The invention is directed to novel methods for reducing the number of apoptotic cell deaths in a population of cells undergoing excessive cellular apoptosis. The invention is also directed to novel methods for preventing apoptotic cell death in a population of cells at risk for developing excessive cellular apoptosis. In particular, the invention is directed to novel methods for reducing or preventing excessive cellular apoptosis comprising exposing cells exhibiting or at risk for developing excessive cellular apoptosis to a novel cellular factor-containing composition called Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS), which is obtained from the culturing of Amnion-derived Multipotent Progenitor (AMP) cells, or AMP cells.Type: ApplicationFiled: February 11, 2015Publication date: June 4, 2015Applicant: STEMNION, INC.Inventors: Howard C. Wessel, Richard A. Banas
-
Publication number: 20150147358Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: ApplicationFiled: February 5, 2015Publication date: May 28, 2015Applicant: Stemnion, Inc.Inventors: Richard A. Banas, Catherine J. Trumpower, Vivienne S. Marshall
-
Patent number: 8877181Abstract: The invention is directed to substantially purified amnion-derived cell populations, compositions comprising the substantially purified amnion-derived cell populations, and to methods of creating such substantially purified amnion-derived cell populations, as well as methods of use. The invention is further directed to antibodies, in particular, monoclonal antibodies, that bind to amnion-derived cells or, alternatively, to one or more amnion-derived cell surface protein markers. The invention is further directed to methods for producing the antibodies, methods for using the antibodies, and kits comprising the antibodies.Type: GrantFiled: October 3, 2012Date of Patent: November 4, 2014Assignee: Stemnion, Inc.Inventors: Charlotte Emig, Vivienne S Marshall, Richard A Banas
-
Publication number: 20140255904Abstract: The invention is directed to methods of modulating ischemic injury in tissues and organs, including donor tissue and organs and intact tissue and organs. The invention is further directed to methods of increasing time to ischemic injury in such tissues and organs. The invention is further directed to storing and preserving donor tissues and organs. Such methods utilize compositions comprising Amnion-derived Cellular Cytokine Solution (herein referred to as ACCS). The ACCS compositions may be formulated for sustained-release, targeted-release, timed-release, extended-release, etc. and may be used alone or in combination with various suitable active agents.Type: ApplicationFiled: March 3, 2014Publication date: September 11, 2014Applicant: Stemnion, Inc.Inventors: Richard A. Banas, David L. Steed, Randall G. Rupp, George L. Sing
-
Patent number: 8647617Abstract: The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.Type: GrantFiled: May 30, 2012Date of Patent: February 11, 2014Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Richard A. Banas, Catherine J. Trumpower